Calling the deal announced late last year an alarming sign for biopharma, the US Federal Trade Commission (FTC) is seeking to block the closing of Amgen’s proposed $28...
Amgen’s proposed acquisition of Horizon Therapeutics for $28.7 billion, including debt, would be the largest healthcare deal since AstraZeneca’s $39 billion purchase of...
Amgen has agreed to buy Horizon Therapeutics for $28.3 billion including debt, boosting its portfolio of drugs for rare autoimmune and inflammatory diseases and beating...
The US Department of Health and Human Services (HHS) said last week it has budgeted $290 million to stock up on Amgen’s Nplate (romiplostim), a drug primarily used to...
Amgen is beefing up its inflammatory diseases portfolio with an agreement to buy US biopharma ChemoCentryx for roughly $3.7 billion. The deal gives Amgen access to...
US biotech Amgen is planning to spend $550 million on building a new biologics manufacturing plant in Holly Springs, Wake County in North Carolina. Construction is...
US biopharma Amgen has agreed to buy privately held clinical-stage biotech Teneobio in a deal worth up to $2.5 billion. The acquisition will expand Amgen’s antibody...
Amgen is to buy Five Prime Therapeutics, a clinical-stage biotech focused on developing immuno-oncology and targeted cancer therapies, for about $1.9 billion. The...
